Sofosbuvir/Ledipasvir (SOF/LDV) has been approved by the European Medicine Agency (EMA) for the treatment of children and adolescents (at least 3 years of age) with chronic hepatitis C (CHC) genotype 1, 3, and 4 infection. The aim of this study was to evaluate the efficacy and safety of SOF/LDV in adolescents (12 to <18 years old) with CHC in the real-world setting.
Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study / Serranti, Daniele; Nebbia, Gabriella; Cananzi, Mara; Nicastro, Emanuele; Di Dato, Fabiola; Nuti, Federica; Garazzino, Silvia; Silvestro, Erika; Giacomet, Vania; Forlanini, Federica; Pinon, Michele; Calvo, Pier Luigi; Riva, Silvia; Dodi, Icilio; Cangelosi, Antonina Marta; Antonucci, Roberto; Ricci, Silvia; Bartolini, Elisa; Mastrangelo, Greta; Trapani, Sandra; Lenge, Matteo; Gaio, Paola; Vajro, Pietro; Iorio, Raffaele; D'Antiga, Lorenzo; Indolfi, Giuseppe. - In: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. - ISSN 0277-2116. - ELETTRONICO. - Publish Ahead of Print:(2020), pp. 0-0. [10.1097/MPG.0000000000002900]
Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study
Serranti, Daniele;Garazzino, Silvia;Dodi, Icilio;Ricci, Silvia;Bartolini, Elisa;Mastrangelo, Greta;Trapani, Sandra;Lenge, Matteo;Indolfi, Giuseppe
2020
Abstract
Sofosbuvir/Ledipasvir (SOF/LDV) has been approved by the European Medicine Agency (EMA) for the treatment of children and adolescents (at least 3 years of age) with chronic hepatitis C (CHC) genotype 1, 3, and 4 infection. The aim of this study was to evaluate the efficacy and safety of SOF/LDV in adolescents (12 to <18 years old) with CHC in the real-world setting.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
